BHIVA national clinical audit of ART Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical audit committee.

Slides:

Advertisements

Similar presentations

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

Advertisements

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

HIV and Hepatitis B or C co-infection Preliminary results of survey.

HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,

MONITORING SYSTEM FOR THE ANTIRETROVIRAL THERAPY IN BRAZIL: LESSONS LEARNED AND FUTURE DIRECTIONS Marco Vitória, MD Brazilian STD/AIDS Programme - MOH.

Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.

BHIVA national clinical audit of HIV diagnosis Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical.

TB and HIV co-infection BHIVA Clinical Audit Sub-Committee: M Backx, C Ball, G Brook, P Bunting, C Carne, A DeRuiter, K Foster, A Freedman, P Gupta, V.

Adolescent transition to adult HIV care Audit & Standards Sub-Committee: M Johnson (chair), M Backx, C Ball, G Brook, D Churchill, A De Ruiter, S Ellis,

Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.

Dr Alison Rodger Royal Free Hospital, London 14 TH A NNUAL C ONFERENCE OF THE B RITISH HIV A SSOCIATION (BHIVA) April 2008, Belfast Waterfront Hall,

HIV testing and diagnosis Dr Simon Ellis On behalf of the Audit & Standards Sub-Committee.

HIV Treatment in Saskatchewan Kurt E. Williams MD FRCPC 2012/Feb/9 Saskatoon.

Introduction to ARV therapy

HIV and Hepatitis B/C Co-infection Audit Audit & Standards Sub-Committee: M Johnson (chair), M Backx, C Ball, G Brook, D Churchill, A De Ruiter, S Ellis,

PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.

DRAFT BHIVA GUIDELINES Routine monitoring of HIV UK-CAB 31 July 2009 Matt Williams writing committee community rep.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

People with diagnosed HIV infection apparently not in care BHIVA in collaboration with Health Protection Agency.

TEMPLATE DESIGN © Improvements of sexual and reproductive healthcare needs of women with HIV in primary care setting W.

Infection Control Clinical Pharmacy and Patient Safety

IMAI Sequence of Care Task shifting, division of labor, and the role of non-clinicians on the care team.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.

UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Catherine Kober Margaret Johnson Martin Fisher Caroline Sabin On behalf of UK-CHIC BHIVA/BASHH Manchester 2010 Non-uptake of HAART among patients with.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.

HIV and maternity BHIVA Clinical Audit BHIVA Clinical Audit Committee Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook,

BHIVA Audit Survey of patient assessment and monitoring Set-up phase of cohort audit of patients starting ART from naïve.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

TB/HIV management survey  Baseline audit in parallel with guidelines development process  Survey of clinician opinion and practice  Data collection.

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.

1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.

TO EVALUATE EARLY ANTIVIRAL RESPONSE AND SAFETY OF A DUAL BOOSTED PROTEASE INHIBITORS REGIMEN INCLUDING LOPINAVIR/r (LPV) PLUS AMPRENAVIR (AMP) OR FORTOVASE.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,

HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.

Networks for HIV clinical care BHIVA Clinical Audit Sub-Committee: J Anderson, M Backx, G Brook, P Bunting, C Carne, G Cairns, A De Ruiter, S Edwards,

Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.

The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Anti Retroviral Treatment Dr. Alap Mehta Senior Medical officer A.R.T. Centre.

Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.

INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.

Potential Utility of Tipranavir in Current Clinical Practice Daniel R. Kuritzkes, MD Director of AIDS Research Brigham and Woman’s Hospital Division of.

Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,

HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.

1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, Dr. Eric Young, MD, MHSc, CCFP,

Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels Presented by Viviane.

Communicating with Patients and Providers HIV Care and ART: A Course for Pharmacists.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

Treatment-Naïve Adults

Diabetes Clinical Audit- July/Aug 2014

TREATMENT OF HIV.

2017 Key Considerations for adolescents and children & Key populations

Pharmacokinetics: HIV Drugs

Pharmacokinetics: HIV Drugs

Believed discrimination occurred because of their:

Poster P200 18th Annual Conference of the British HIV Association (BHIVA), 18 – 20th April 2012, Birmingham, UK An analysis of the reasons for switching.

Claire Gamble Friday 30th June 2017

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

Presentation transcript:

BHIVA national clinical audit of ART Dr Margaret Johnson, Chair of BHIVA clinical audit committee Dr Gary Brook Vice-Chair of BHIVA clinical audit committee Dr Hilary Curtis, BHIVA clinical audit co-ordinator Committee: R Brettle, P Bunting, A Freedman, B Gazzard, C O’Mahony, E Monteiro, D Mital, F Mulcahy, A Pozniak, K Radcliffe, C Sabin, A Sullivan, A Tang, J Welch, E Wilkins

2002 audit preliminary results Survey of:  Clinic practice & policies on treatment initiation  Follow-up of 2001 audit  Arrangements for maternity care Case note review:  Patients starting treatment from naive

Characteristics of participating centres 90 centres stated their actual case-load (HIV patients seen in preceding 6 months). The total for these 90 centres was NB totals do not add because some centres did not state their size and/or region.

Growth in HIV case-loads over past year Percentage of centres Change in number of cases

Local policies on starting treatment  84 (74%) centres say their policy is to follow BHIVA guidelines  15 (13%) have local policy/guidelines which supplement BHIVA  4 (4%) have no local policy/guidelines  10 (9%) did not answer.  38 (34%) have local policy/guidelines on adherence  66 (58%) do not  9 (8%) did not answer.

Restrictions on choice of ART drugs  99 (88%) of centres have no restrictions  2 (2%) have restrictions due to cost  2 (2%) have restrictions due to clinic policy  1 (1%) has restrictions for other reasons  9 (8%) did not answer.

Clinics’ stated practice re follow-up of patients starting ART from naive First review of patients starting ART:  71 (63%) of centres within 1-2 weeks  33 (29%) at 2-4 weeks  2 (2%) at 4-8 weeks  7 (6%) did not answer. First VL after starting ART:  43 (39%) of centres within 4 weeks  20 (18%) at 6 weeks  20 (18%) at 7-8 weeks  20 (18%) at weeks  10 (9%) did not answer.

Pharmacy arrangements 34 centres (31%) have dedicated HIV pharmacist support – however, as these are larger centres they serve 73% of the total reported patient case-load. 20 centres (18%, serving 6% of caseload) have pharmacist(s) with a special interest in HIV and 42 (38%, serving 14% of caseload) use generic hospital pharmacy services. 1 centre (1%, serving 0.2% of caseload) used community pharmacists and 13 (12%, serving 7% of caseload) did not say.

Patient data: starting treatment from naive 942 patients:  56% male, 44% female  55% Black-African, 36% white Stated reasons for starting treatment included:  Disease progression 802 patients (85%)  Prevention of vertical transmission 117 (12%) – 92 as sole reason  Patient choice 88 (9%) – 2 as sole reason both in fact with CD4 <230  High viral load 275 (29%) – 9 as sole reason of whom 6 in fact had CD4 < 200 and/or CDC B/C  Recent seroconversion 25 (3%)

Delay between diagnosis and starting treatment Number of patients Pre-treatment CD4

Tests done prior to treatment

Tests done prior to treatment % of patients tested

HIV resistance testing done prior to treatment? % of patients

65 different combinations were reported. 844 (89.6%) patients had been started on “standard” combinations as recommended in BHIVA guidelines – shown left:  311 Combivir ® /efavirenz  203 Combivir ® /nevirapine  35 Combivir ® /lopinavir/r  29 Combivir ® /nelfinavir  87 Trizivir ®  23 Combivir ® /abacavir. Drug combinations *single or boosted

“Non-standard” combinations Reasons for choosing non- standard combinations included:  Efficacy (42 patients)  Physician preference (36)  Dosage/convenience (35)  Toxicity minimisation (29)  Clinical trial (25)  Patient choice (22)  Concomitant disease/ medication (20)

Use of tenofovir 42 patients had been started on tenofovir, including 19 on lamivudine/efavirenz/tenofovir. Reasons included:  dosage/convenience (22 patients, including 12 started on lamivudine/efavirenz/tenofovir)  efficacy (19 patients, including 8 started on lamivudine/efavirenz/tenofovir & 3 on Combivir ® /efarivenz/tenofovir)  toxicity minimisation (16 patients including 3 lamivudine/efavirenz/tenofovir & 3 Combivir ® /efavirenz/tenofovir)  patient choice (14 patients, including 10 lamivudine/efavirenz/tenofovir)  clinical trial (5 patients)  concomitant disease or medication (19 patients, including 6 TB, 9 hepatitis B of whom 7 also on lamivudine, 1 hepatitis C, 5 other)

Management of HIV and pregnancy

Antenatal testing rates

Follow-up of 2001 audit Feedback sessions were attended by:  Physician(s) at 41 centres  Nurse(s) at 29 centres  Pharmacist(s) at 10 centres  Other(s) at 13 centres

Completing the audit cycle The large number of centres reporting no need for change reflects the generally positive findings of the 2001 audit.

Summary: key points Most centres report >15% rise in HIV caseload over past year. 38% of centres do not test VL until > 6 weeks after starting ART. Significant delays can occur between diagnosis and starting ART even for patients with extremely low CD4. BP, glucose +/or lipids were not measured before starting ART in a substantial proportion of patients. Although many different drug combinations were used, most patients started on 2NRTI/NNRTI or other standard HAART.